Endosomal Control of Microbe-Host Homeostasis
微生物宿主稳态的内体控制
基本信息
- 批准号:8874972
- 负责人:
- 金额:$ 34.44万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2014
- 资助国家:美国
- 起止时间:2014-07-01 至 2019-06-30
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
DESCRIPTION (provided by applicant): The intestinal epithelium (IEC) with its luminal microflora serves as an ideal experimental and medical model that merges innate immune recognition in the context of a tissue regeneration environment. Genetic predispositions that cause imbalanced microbe-host interaction may contribute to the pathogenesis of inflammatory bowel disease (IBD). Various susceptibility loci for Crohn's disease and ulcerative colitis have been identified; however, their contributions to the disease mechanism remain poorly defined. A Crohn's disease susceptibility locus at chromosome 15q22 is immediately linked to RAB11A. This gene encodes a small guanosine triphosphatase (GTPase) that regulates the recycling endosome function. The applicant's laboratory has genetically targeted the mouse Rab11a, and analyzed IEC-specific Rab11a knockout mice. Preliminary data suggested that Rab11a controls epithelial-cell-intrinsic inflammatory cytokine response to enteric microbiota. Enterocytes deficient in Rab11a in Drosophila and mouse intestines overproduced proinflammatory cytokines, and caused early-onset enteritis, higher susceptibility to inflammatory neoplasia, and premature mortality. The long- term goal is to understand how the endosomal sorting of microbial receptors in IECs influences innate mucosal immunity and microbe-host homeostasis. The objective of this proposal is to establish the molecular mechanisms, by which Rab11a endosome-mediated sorting of Toll-like receptors (TLRs), in particular TLR9, support intestinal mucosal tolerance to microbiota. The central hypothesis is that Rab11a sequesters TLR9 to an inactive endosomeal compartment and dampens unwanted immune response to enteric microbiota at steady state conditions. Information learned about IEC-mediated modulation of inflammatory cytokine production and immune response may help reduce the adverse inflammatory response in IBD. This hypothesis will be tested with 2 specific aims: (1) to establish Rab11a endosomal compartment as an epithelial-cell-intrinsic modulator of cytokine response to microbiota; and (2) to determine the mechanism of Rab11a-controlled TLR9 transport and activation in response to microbial agonists. The experiments will use the novel Rab11a conditional mouse model that facilitates inducible Rab11a deletion, IEC-specific Drosophila Rab11 RNA interference (RNAi) lines, RAB11A-depleted human colon epithelial cell lines, and in vivo perfusion of microbial agonists. The combination of these genetic models with in vivo physiologic analyses in the study of endocytic control of microbe-host homeostasis is innovative and a major step toward understanding IBD.
描述(由申请人提供):肠上皮(IEC)及其发光菌群是一种理想的实验和医学模型,在组织再生环境的背景下合并了先天免疫识别。引起微生物宿主相互作用不平衡的遗传易感性可能有助于炎症性肠病(IBD)的发病机理。已经发现了克罗恩病和溃疡性结肠炎的各种敏感位点;但是,它们对疾病机制的贡献仍然很差。 15q22染色体的克罗恩病敏感性基因座立即与Rab11a相关。该基因编码一个小的鸟嘌呤三磷酸酶(GTPase),该三磷酸酶(GTPase)调节回收内体功能。申请人的实验室已遗传针对小鼠RAB11A,并分析了IEC特异性RAB11A敲除小鼠。初步数据表明,RAB11A控制上皮细胞内炎性细胞因子对肠菌群的反应。果蝇和小鼠肠中Rab11a缺乏的肠细胞过量产生了促炎细胞因子,并引起早发性肠炎,较高的炎症性肿瘤易感性和过早死亡。长期的目标是了解IEC中微生物受体的内体分选如何影响先天粘膜免疫和微生物宿主体内平衡。该提案的目的是建立分子机制,rab11a内体介导的Toll样受体(TLR)的分类,特别是TLR9,支持对微生物群的肠粘膜耐受性。中心假设是Rab11a将TLR9隔离为无活性的内体室,并在稳态条件下抑制对肠性微生物群的不良免疫反应。有关IEC介导的炎症细胞因子产生和免疫反应调节的信息可能有助于减少IBD的不良炎症反应。该假设将以2个特定的目的进行检验:(1)将Rab11a内体室建立为细胞因子对微生物群的上皮细胞内膜调节剂; (2)确定Rab11a控制的TLR9转运和激活对微生物激动剂的机制。该实验将使用新型的RAB11A条件小鼠模型,该模型促进了可诱导的Rab11a缺失,IEC特异性果蝇Rab11 RNA干扰(RNAI)线,RAB11A耗尽的人类结肠上皮细胞系,以及微生物养老金的体内灌注。这些遗传模型与体内生理分析的组合在对微生物宿主体内稳态的内吞控制的研究中是创新的,也是理解IBD的重要一步。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

暂无数据
数据更新时间:2024-06-01
Nan Gao的其他基金
Paneth cell heterogeneity in infection and inflammation
感染和炎症中的潘氏细胞异质性
- 批准号:1059239710592397
- 财政年份:2022
- 资助金额:$ 34.44万$ 34.44万
- 项目类别:
Paneth cell heterogeneity in infection and inflammation
感染和炎症中的潘氏细胞异质性
- 批准号:1046722710467227
- 财政年份:2022
- 资助金额:$ 34.44万$ 34.44万
- 项目类别:
Intestinal lysozyme controls mucosal immune response to microbiota
肠道溶菌酶控制对微生物群的粘膜免疫反应
- 批准号:1064022110640221
- 财政年份:2019
- 资助金额:$ 34.44万$ 34.44万
- 项目类别:
Intestinal lysozyme controls mucosal immune response to microbiota
肠道溶菌酶控制对微生物群的粘膜免疫反应
- 批准号:1020612610206126
- 财政年份:2019
- 资助金额:$ 34.44万$ 34.44万
- 项目类别:
Intestinal lysozyme controls mucosal immune response to microbiota
肠道溶菌酶控制对微生物群的粘膜免疫反应
- 批准号:1042723910427239
- 财政年份:2019
- 资助金额:$ 34.44万$ 34.44万
- 项目类别:
Research Supplements to Promote Diversity in Health-Related Research
促进健康相关研究多样性的研究补充
- 批准号:1035627110356271
- 财政年份:2019
- 资助金额:$ 34.44万$ 34.44万
- 项目类别:
Endosomal Control of Microbe-Host Homeostasis
微生物宿主稳态的内体控制
- 批准号:92844729284472
- 财政年份:2014
- 资助金额:$ 34.44万$ 34.44万
- 项目类别:
Endosomal Control of Microbe-Host Homeostasis
微生物宿主稳态的内体控制
- 批准号:90698209069820
- 财政年份:2014
- 资助金额:$ 34.44万$ 34.44万
- 项目类别:
Endosomal Control of Microbe-Host Homeostasis
微生物宿主稳态的内体控制
- 批准号:87659658765965
- 财政年份:2014
- 资助金额:$ 34.44万$ 34.44万
- 项目类别:
Abrogating a survival pathway in early colon cancer cells
废除早期结肠癌细胞的生存途径
- 批准号:86881908688190
- 财政年份:2013
- 资助金额:$ 34.44万$ 34.44万
- 项目类别:
相似国自然基金
玛纳斯河流域上游吸收性气溶胶来源及其对积雪消融的影响研究
- 批准号:42307523
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
面向肝癌射频消融的智能建模与快速动力学分析方法研究及其临床验证
- 批准号:62372469
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
IRF9调控CD8+T细胞介导微波消融联合TIGIT单抗协同增效抗肿瘤的作用机制
- 批准号:82373219
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
建立可诱导细胞消融系统揭示成纤维细胞在墨西哥钝口螈肢体发育及再生中的作用
- 批准号:32300701
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
肿瘤源PPIA介导结直肠癌肝转移射频消融术残瘤化疗抵抗的机制研究
- 批准号:82302332
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
相似海外基金
Formation of a functional tendon enthesis during development and healing
在发育和愈合过程中形成功能性肌腱附着点
- 批准号:1058739910587399
- 财政年份:2023
- 资助金额:$ 34.44万$ 34.44万
- 项目类别:
Integrated Molecular and Cellular Drivers of Alveologenesis
肺泡发生的综合分子和细胞驱动因素
- 批准号:1063776410637764
- 财政年份:2023
- 资助金额:$ 34.44万$ 34.44万
- 项目类别:
Isolating the role of endogenous mu-opioid activity in the VTA during natural reward
分离自然奖赏期间 VTA 中内源性 mu-阿片活性的作用
- 批准号:1074934910749349
- 财政年份:2023
- 资助金额:$ 34.44万$ 34.44万
- 项目类别:
Targeting GPR84 to Overcome Macrophage Mediated Resistance to Immunotherapy
靶向 GPR84 克服巨噬细胞介导的免疫治疗耐药性
- 批准号:1066012210660122
- 财政年份:2023
- 资助金额:$ 34.44万$ 34.44万
- 项目类别:
CLEC7A in microglia biology and Alzheimer's disease
CLEC7A 在小胶质细胞生物学和阿尔茨海默病中的作用
- 批准号:1065994010659940
- 财政年份:2023
- 资助金额:$ 34.44万$ 34.44万
- 项目类别: